Cancer-induced hypercalcemia

Anticancer Research

Volumn 29, Issue 5, 2009, Pages 1551-1555

  Lumachi, Franco ^a   Brunello, Antonella ^b   Roma, Anna ^b   Basso, Umberto ^b  

^a UNIVERSITY OF PADOVA   (Italy)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

Author keywords

Bisphosphonates; Cancer; Hypercalcemia; Malignancy; PTHrP; RANKL; Review

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; DENOSUMAB; GALLIUM NITRATE; MITHRAMYCIN; OSTEOCLAST DIFFERENTIATION FACTOR; PARATHYROID HORMONE RELATED PROTEIN;

CALCIUM BLOOD LEVEL; CANCER INDUCED HYPERCALCEMIA; CELL ACTIVATION; CELL INTERACTION; HORMONE BLOOD LEVEL; HUMAN; HYPERCALCEMIA; KIDNEY FUNCTION; MEDICAL INFORMATION; NEOPLASM; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; REVIEW; UNSPECIFIED SIDE EFFECT; URINARY EXCRETION;

DIPHOSPHONATES; HUMANS; HYPERCALCEMIA; NEOPLASMS; PARATHYROID HORMONE-RELATED PROTEIN;

EID: 67650083197     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Case records of the Massachusetts General Hospital: Case 27461. N Engl J Med 319: 225-227, 1941.
2. Grill V and Martin TJ: Hypercalcemia of malignancy. Rev Endocr Metab Disord 1: 245-263, 2000.
3. Strewler GJ: Humoral manifestations of malignancy. In: Basic & Clinical Endocrinology. Greenspan FS and Strewler GJ (eds.). Stamford, CT, Appleton Lange, pp. 741-752, 1997.
4. Shoback D and Funk J: Humoral manifestations of malignancy. In: Basic & Clinical Endocrinology. Greenspan FS and Gardner DG (eds.). New York, NY, Lange Medical Book/McGraw-Hill, pp. 778-791, 2001.
5. Strewler GJ: Hypercalcemia of malignancy and parathyroid hormone-related protein. In: Textbook of Endocrinesurgery. Clark OH, Duh Q-Y and Kebebew E (eds.). Philadelphia, PA, Elsevier Saunders, pp. 536-542, 2005.
6. Lumachi F et al: Medical treatment of malignancy-associated hypercalcemia. Curr Med Chem 15: 415-421, 2008.
7. Rosol TJ and Capen CC: Mechanism of cancer-induced hypercalcemia. Lab Invest 67: 680-702, 1992.
8. Montell D: Metastasis movies, macrophages, molecules and more. Conference on Mechanisms of Invasion and Metastasis. EMBO Rep 4: 458-462, 2003.
9. Kronemberg HM: Developmental regulation of the growth plate. Nature 423: 332-336, 2003.
10. Mundy GR: Metastasis to bone: causes, consequences and therapeutics opportunities. Nat Rev Cancer 2: 584-593, 2002. (Pubitemid 37328925)
11. Wimalawansa SJ: Significance of plasma PTHrP in patients with hypercalcemia of malignancy treated with bisphosphonates. Cancer 73: 2223-2230, 1994. (Pubitemid 24107981)
12. Lumachi F et al: Parathyroid cancer: etiology, clinical presentation and treatment. Anticancer Res 26: 4803-4807, 2006. (Pubitemid 46032116)
13. Lumachi F et al: Technetium-99m sestamibi scintigraphy and helical CT together in patients with primary hyperparathyroidism: a prospective clinical study. Brit J Radiol 77: 100-103, 2004. (Pubitemid 38313221)
14. Lumachi F et al: PCNA-Li, Ki 67 immunostaining, p53 activity and histopathological variables in predicting the clinical outcome in patients with parathyroid carcinoma. Anticancer Res 26: 1305-1308, 2006.
15. Heath DA: Hypercalcemia of malignancy. In: Russell RGG and Kanis JA (eds.). Tumor-induced Hypercalcemia and its Management. London, Royal Society of Medicine, pp. 29-32, 1991.
16. Strewler GL: Mineral metabolism and metabolic bone diseases. In: Basic and Clinical Endocrinology, 5th Edition. Greenspan FS and Strewler GJ (eds.). Stamford, CT, Appleton Lange, pp. 263-316, 1997.
17. Compston JE: Investigation of hypocalcemia. Clin Endocrinol 42: 195-198, 1995.
18. Ralston SH, Coleman R, Fraser WD et al: Medical management of hypercalcemia. Calcif Tiss Int 74: 1-11, 2004.
19. Roges MJ: New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des 9: 2643-2658, 2003. (Pubitemid 37456015)
20. Ross JR et al: Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer. Brit Med J 327: 469-471, 2003. (Pubitemid 37056193)
21. Lumachi F and Basso SM: Apoptosis: life through planned cellular death. Regulating mechanism, control systems, and relations with thyroid diseases. Thyroid 12: 27-34, 2002.
22. Fleisch H: Bisphosphonates: mechanisms of action. Endocr Rev 19: 80-100, 1998.
23. Brown EJ and Coleman RE: The role of bisphosphonates in breast cancer: The present and future role of bisphosphonates in the management of patients with breast cancer. Breast Cancer Res 4: 24-29, 2002.
24. Weitzman R et al: Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients-May 2006. Crit Rev Oncol Hematol 62: 148-152, 2007.
25. Fatemi S et al: Effect of salmon calcitonin and etidronate on hypercalcemia of malignancy. Calcif Tissue Int 50: 107-109, 1992.
26. Vinholes J et al: Evaluation of new bone resorption markers in a randomized comparison of pamidronate or clodronate for hypercalcemia of malignancy. J Clin Oncol 15: 131-138, 1997. (Pubitemid 27020566)
27. Thürlimann B et al: Plicamycin and pamidronate in symptomatic tumor-related hypercalcemia: a prospective randomized crossover trial. Ann Oncol 3: 589-590, 1992.
28. Santini D et al: The antineoplastic role of bisphosphonates: from basic research to clinical evidence. Ann Oncol 14: 1468-1476, 2003. (Pubitemid 37304600)
29. Body JJ et al: A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 12: 1221-1228, 2006. (Pubitemid 43342512)
30. Major P et al: Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 19: 558-567, 2001. (Pubitemid 32112871)
31. Body JJ et al: A dose-finding study of zoledronate in hypercalcemic cancer patients. J Bone Min Res 14: 1557-1561, 1999. (Pubitemid 29416682)
32. Percherstrofer M et al: Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: a randomized multicentric comparison to pamidronate. Suppl Care Cancer 11: 539-547, 2003. (Pubitemid 36994438)
33. Zojer N et al: Bisphosphonate treatment does not affect serum levels of osteoprotegerin and RANKL in hypercalcemic cancer patients. Anticancer Res 25: 3607-3612, 2005. (Pubitemid 41105249)
34. Bockman R: The effects of gallium nitrate on bone resorption. Semin Oncol 30: 5-12, 2003. (Pubitemid 36618327)
35. Cvitkovic F et al: Randomized, double-blind, phase II trial of gallium nitrate compared with pamidronate for acute control of cancer-related hypercalcemia. Cancer 12: 47-53, 2006.
36. Leyland-Jones B: Treating cancer-correlated hypercalcemia with gallium nitrate. J Support Oncol 2: 509-516, 2004. (Pubitemid 40100639)
37. Diskin CJ et al: Malignancy-related hypercalcemia developing on a bisphosphonate but responding to calcitonin. Clin Lung Cancer 8: 434-435, 2007. (Pubitemid 47242443)
38. Tanaka S et al: Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system. Immun Rev 208: 30-49, 2005. (Pubitemid 41746383)
39. Morony S et al: The inhibition of RANKL causes greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hypercalcemia in malignancy. Endocrinology 146: 3235-3243, 2005. (Pubitemid 41058092)
40. Stewart AF: Clinical practice. Hypercalcemia associated with cancer. N Engl J Med 352: 373-379, 2005.
41. Bekker PJ et al: A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Min Res 19: 1059-1066, 2004. (Pubitemid 41110556)
42. Morony S et al: The inhibition of RANKL causes greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hypercalcemia in malignancy. Endocrinology 146: 3235-3243, 2005. (Pubitemid 41058092)
43. McClung MR et al: Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354: 821-831, 2006. (Pubitemid 43290920)
44. Sato K et al: Treatment of malignancy-associated hypercalcemia and cachexia with humanized anti-parathyroid hormone-related protein antibody. Semin Oncol 30: 167-173, 2003. (Pubitemid 37433408)
45. Onuma E et al: Increased renal calcium reabsorption by parathyroid hormone-related protein is a causative factor in the development of humoral hypercalcemia of malignancy refractory to osteoclastic bone resorption inhibitors. Clin Cancer Res 11: 4198-4203, 2005. (Pubitemid 40791586)